Skip to main content Accessibility help
×
×
Home

Controlled efficacy study of fluoxetine in dysthymia

  • Jean-Marie Vanelle (a1), Dominique Attar-Levy (a1), Marie-France Poirier (a1), Myriam Bouhassira (a2), Patrick Blin (a3) and Jean-Pierre Olié (a4)...

Abstract

Background

There have been very few controlled studies of antidepressants in dysthymia, particularly in samples diagnosed reliably and with an adequate length of follow-up. In this investigation, we measured the long-term outcome in a large group of patients meeting DSM – III -R criteria for dysthymia. This study was designed to investigate whether fluoxetine is effective in the treatment of dysthymia.

Method

This randomised study, including 140 patients, compared fluoxetine (91 patients) and placebo (49 patients) on a double-blind basis in two distinct phases: a short-term end-point (3 months with 20 mg/day fluoxetine) and a medium-term end-point (6 months) where the initial responders continued double-blind treatment unchanged and non-responders received an additional treatment of 20 mg/day fluoxetine.

Results

After three months of treatment, response was seen more frequently in the fluoxetine group (42/72) than in the placebo group (14/39, P <0.0001). Improved patients at 3 months were still improved at 6 months. Furthermore, 50% of the non-responders at 3 months improved and rated as responders at 6 months, after fluoxetine was increased to 40 mg daily.

Conclusions

This study showed the significant and persistent action of fluoxetine on dysthymia. The finding that 50% of the non-responders at 3 months were improved at 6 months, after fluoxetine dosage was increased to 40 mg daily, argues in favour of treating dysthymic patients for at least 6 months, and with a higher dosage if the initial doses are ineffective.

Copyright

Corresponding author

Dr Jean-Marie Vanelle, Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre Hospitalier Sainte Anne, I Rue Cabanis, 75014 Paris, France

References

Hide All
Akiskal, H. S. (1983) Dysthymic disorders: psychopathology of proposed chronic depressive subtypes. American Journal of Psychiatry, 140, 1120.
Akiskal, H. S. (1993) La dysthymie et son traitement. Encéphale, 19, 375378.
Akiskal, H. S. & Akiskal, K. (1992) Cyclothymic, hyperthymic and depressive temperaments as subaffective variants of mood disorders. In American Psychiatric Association Review (eds Tasman, A. & Riba, M. B.), pp. 4362. Washington. DC: APA.
Alby, J. M., Cabane, J., Ferreri, M., et al (1993) Efficacy and acceptability of tianeptine in major depressive disorder and in dysthymia (DSM-III-R) with somatic complaints: double-blind study versus fluoxetine. European Neuropsychopharmacology, 3, 333.
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM – III). Washington. DC: APA.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn. revised) (DSM-III-R). Washington. DC: APA
Baldwin, D., Budge, S. & Thomas, S. (1995) Dysthymia: options in pharmacotherapy. CNS Drugs, 4, 422431.
Derogatis, L. R., Lipman, R. S., Rkkels, K., et al (1974) The Hopkins Symptoms Checklist (HSCL): a self-report symptom inventory. Behavioural Sciences. 19, 115.
Freeman, H. L. (1994) Historical and nosological aspects of dysthymia. Acta Psychiatrica Scandinavie, 89 (suppl.). 711.
Guy, W. (1976) Assessment Manual for Psychopharmacology Bethesda, MD: National Institute of Mental Health
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.
Hellerstein, D J., Yanowtich, P., Rosenthal, J., et al (1993) A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. American Journal of Psychiatry, 150, 11691175.
Leboyer, M., Teherani, M., Lepine, J. P. (1992) Schedule for Affective Disorders and Schizophrenia, Lifetime Version. Traduction et Adaptation Française. Paris: Doin.
Rabkin, J. G., McGrath, P. J., Quitkin, F. M., et al (1990) Effects of pill-giving on maintenance of placebo response in patients with chronic mild depression. American Journal of Psychiatry, 147, 16221626.
Ravindran, A. V., Bialik, R. J. & Lapierre, Y. D. (1994) Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Canadian Journal of Psychiatry, 39, 2126.
Rosenthal, J., Hemlock, C., Hellerstein, D. J., et al (1992) A preliminary study of serotoninergic antidepressants in treatment of dysthymia. Progress in Neuropsychopharmacology and Biological Psychiatry, 16, 933941.
Weissman, M. M., Leaf, P. J., Bruce, M. L., et al (1960) The epidemiology of dysthymia in five communities: rates, risks, comorbidity and treatment. American Jurnal of Psychiatry, 145, 815819.
WPA Dysthymia Working Group (1995) Dysthymia in clinical practice. British Journal of Psychiatry, 166, 174183.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Controlled efficacy study of fluoxetine in dysthymia

  • Jean-Marie Vanelle (a1), Dominique Attar-Levy (a1), Marie-France Poirier (a1), Myriam Bouhassira (a2), Patrick Blin (a3) and Jean-Pierre Olié (a4)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *